Clinical course of 2019 novel coronavirus disease (COVID-19) in individuals present during the outbreak on the Diamond Princess cruise ship

      Abstract

      We investigated the clinical course of individuals with 2019 novel coronavirus disease (COVID-19) who were transferred from the Diamond Princess cruise ship to 12 local hospitals. The conditions and clinical courses of patients with pneumonia were compared with those of patients without pneumonia. Among 70 patients (median age: 67 years) analyzed, the major symptoms were fever (64.3%), cough (54.3%), and general fatigue (24.3%). Forty-three patients (61.4%) had pneumonia. Higher body temperature, heart rate, and respiratory rate as well as higher of lactate dehydrogenase (LDH), aspartate aminotransferase (AST), and C-reactive protein (CRP) levels and lower serum albumin level and lymphocyte count were associated with the presence of pneumonia. Ground-glass opacity was found in 97.7% of the patients with pneumonia. Patients were administered neuraminidase inhibitors (20%), lopinavir/ritonavir (32.9%), and ciclesonide inhalation (11.4%). Mechanical ventilation and veno-venous extracorporeal membrane oxygenation was performed on 14 (20%) and 2 (2.9%) patients, respectively; two patients died. The median duration of intubation was 12 days. The patients with COVID-19 transferred to local hospitals during the outbreak had severe conditions and needed close monitoring. The severity of COVID-19 depends on the presence of pneumonia. High serum LDH, AST and CRP levels and low serum albumin level and lymphocyte count were found to be predictors of pneumonia. It was challenging for local hospitals to admit and treat these patients during the outbreak of COVID-19. Assessment of severity was crucial to manage a large number of patients.

      Keywords

      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to Journal of Infection and Chemotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Diamond Princess Updates
        (Feb 6 [cited 2020 Mar 7])
        • National Institute of Infectious Diseases
        Field briefing: Diamond princess COVID-19 cases.
        2020 (20 Feb Update) (Feb 21. [cited 2020 Mar 7])
        • Takeuchi I.
        COVID-19 first stage in Japan - how we treat Diamond princess cruise ship with 3700 passengers?.
        Acute Med Surg. 2020; 7: e506https://doi.org/10.1002/ams2.506
        • World Health Organization
        Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected.
        2020 (Interim guidance 13 March 2020) (Mar 13 [cited Mar 19])
        • Zhou F.
        • Yu T.
        • Du R.
        • Fan G.
        • Liu Y.
        • Liu Z.
        • et al.
        Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.
        Lancet. 2020; 395: 1054-1062https://doi.org/10.1016/S0140-6736(20)30566-3
        • Guan W.J.
        • Ni Z.Y.
        • Hu Y.
        • Fan G.
        • Liu Y.
        • Liu Z.
        • et al.
        Clinical characteristics of coronavirus disease 2019 in China.
        N Engl J Med. 2020; 382: 1708-1720https://doi.org/10.1056/NEJMoa2002032
        • Cruise Lines International Association
        2017 Asia cruise report.
        2017 (Jul [cited 2020 Mar 7])
        • Rocklöv J.
        • Sjödin H.
        • Wilder-Smith A.
        COVID-19 outbreak on the Diamond Princess cruise ship: estimating the epidemic potential and effectiveness of public health countermeasures.
        J Trav Med. 2020; (taaa030)https://doi.org/10.1093/jtm/taaa030
        • Wang D.
        • Hu B.
        • Hu C.
        • Zhu F.
        • Liu X.
        • Zhang J.
        • et al.
        Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China.
        J Am Med Assoc. 2020; e201585https://doi.org/10.1001/jama.2020.1585
        • Pan F.
        • Ye T.
        • Sun P.
        • Gui S.
        • Liang B.
        • Li Lingli
        • et al.
        Time course of lung changes on chest CT during recovery from 2019 novel coronavirus (COVID-19) pneumonia.
        Radiology. 2020; : 200370https://doi.org/10.1148/radiol.2020200370
        • Xie X.
        • Zhong Z.
        • Zhao W.
        • Zheng C.
        • Wang F.
        • Liu J.
        Chest CT for typical 2019-nCoV pneumonia: relationship to negative RT-PCR testing.
        Radiology. 2020; : 200343https://doi.org/10.1148/radiol.2020200343
        • Nakajima K.
        • Ogawa F.
        • Sakai K.
        • Uchiyama M.
        • Oyama Y.
        • Kato H.
        • et al.
        A case of coronavirus disease 2019 treated with ciclesonide.
        Mayo Clin Proc. 2020; ([In press])https://doi.org/10.1016/j.mayocp.2020.04.007
        • Iwabuchi K.
        • Yoshie K.
        • Kurakami Y.
        • Takahashi K.
        • Kato Y.
        • Morishita T.
        Therapeutic potential of ciclesonide inahalation for COVID-19 pneumonia: report of three cases.
        J Infect Chemother. 2020; ([in press])https://doi.org/10.1016/j.jiac.2020.04.007